4.3 Article

Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study

Mirabella Zhao et al.

Summary: The study found low persistence rates for first-line biologicals among IBD patients, with one-third switching treatment. Surgery rates decreased over time, but whether this is related to the use of biologicals has yet to be determined.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Gastroenterology & Hepatology

Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

Ligia Yukie Sassaki et al.

Summary: The study compared clinical and endoscopic remission rates between adalimumab and infliximab in Brazilian UC patients, showing higher remission rates with infliximab. Factors associated with higher clinical remission rates included no prior exposure to biological therapy and early response to anti-TNF treatment.

BMC GASTROENTEROLOGY (2022)

Article Medicine, General & Internal

Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases

Janvi Sah et al.

Summary: This study evaluated the treatment patterns of biologics in patients with moderate-to-severe ulcerative colitis. The results showed that VDZ had the highest persistence among patients, followed by IFX, GOL, and ADA.

CURRENT MEDICAL RESEARCH AND OPINION (2022)

Article Gastroenterology & Hepatology

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Aviv Pudipeddi et al.

Summary: In moderate-to-severe ulcerative colitis (UC), vedolizumab (VED) has significantly longer persistence as a first-line biological agent compared to infliximab (IFX), but it does not disadvantage the use of second-line IFX. However, the use of VED after IFX failure is associated with poorer persistence. Therefore, VED should be considered as the first-line biological agent of choice in UC.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Article Gastroenterology & Hepatology

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

Matthew Bohm et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Article Public, Environmental & Occupational Health

Validity of Antineoplastic Procedure Codes in the Danish National Patient Registry The Case of Colorectal Cancer

Martin Oskar Broe et al.

EPIDEMIOLOGY (2020)

Article Gastroenterology & Hepatology

Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014

Lone Larsen et al.

INFLAMMATORY BOWEL DISEASES (2018)

Article Pharmacology & Pharmacy

Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease

Joanne E. Brady et al.

CLINICAL THERAPEUTICS (2018)

Article Gastroenterology & Hepatology

Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience

Pablo Olivera et al.

INFLAMMATORY BOWEL DISEASES (2017)

Article Gastroenterology & Hepatology

Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis

Laura E. Targownik et al.

INFLAMMATORY BOWEL DISEASES (2017)

Review Medicine, General & Internal

Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis

Marla C. Dubinsky

POSTGRADUATE MEDICINE (2017)

Article Gastroenterology & Hepatology

The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study

S. N. Lophaven et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)

Article Gastroenterology & Hepatology

Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis

S. Singh et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)

Review Public, Environmental & Occupational Health

The Danish National Patient Registry: a review of content, data quality, and research potential

Morten Schmidt et al.

CLINICAL EPIDEMIOLOGY (2015)

Article Gastroenterology & Hepatology

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

Mark T. Osterman et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)

Review Public, Environmental & Occupational Health

The Danish Civil Registration System as a tool in epidemiology

Morten Schmidt et al.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)

Article Public, Environmental & Occupational Health

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

Hude Quan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)

Article Public, Environmental & Occupational Health

Danish education registers

Vibeke M. Jensen et al.

SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)

Article Public, Environmental & Occupational Health

Danish registers on personal income and transfer payments

Mikkel Baadsgaard et al.

SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)

Review Gastroenterology & Hepatology

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Asher Kornbluth et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)